Lifebit R.E.A.L.

Lifebit R.E.A.L. offers a sophisticated real-time surveillance system designed to detect adverse drug reactions (ADRs) using AI-driven analysis. Engineered for both regulatory bodies and research organizations, it transforms global real-world data into prompt insights, allowing for immediate identification and response to potential ADR trends and risks.

Key features of the platform include:

• Automated ADR Signal Detection: Utilizes AI to automatically detect potential adverse drug reactions, minimizing the need for manual intervention and providing real-time updates.
• Regulatory Compliance: Adheres to FedRAMP, HIPAA, GDPR, and FDA standards, ensuring secure and compliant operation across various health and research settings.
• Trusted by Industry Leaders: Deployed by national health agencies and major pharmaceutical companies worldwide, showcasing its reliability and scalability.

The platform continuously monitors extensive data sources, from electronic health records to social media, enabling users to track signals, assess risks, and take proactive actions swiftly. Its interactive dashboards allow for easy visualization and analysis of case data, filtered by drug, demographic, or clinical outcome.

AI models within Lifebit R.E.A.L. rank ADR signals according to severity and prevalence, helping prioritize critical incidents. Organizations can export data, generate reports, and share detailed insights with traceable and reproducible results, facilitating both internal reviews and regulatory reporting.

Designed for rapid deployment, Lifebit R.E.A.L. can be operational within a day in secure cloud environments, integrating seamlessly with custom AI models and other platforms like SageMaker. This capability ensures reduced costs, enhanced computational efficiency, and a significant reduction in surveillance time, making it an indispensable component of modern pharmacovigilance efforts.